Form 4: OrbiMed Advisors Reduces Stake in Disc Medicine Through Multiple Transactions

OrbiMed Advisors LLC and related entities have sold shares of Disc Medicine, Inc. (IRON) common stock in a series of transactions between March 10, 2025, and March 12, 2025, while maintaining indirect beneficial ownership.

Summary

• OrbiMed Advisors LLC, along with related entities including OrbiMed Capital GP VI LLC, OrbiMed Capital GP VIII LLC, and OrbiMed Genesis GP LLC, filed a Form 4 detailing changes in beneficial ownership of Disc Medicine, Inc. (IRON) common stock.
• Between March 10 and March 12, 2025, OrbiMed entities sold shares of IRON at prices ranging from $54.00 to $55.11 per share.
• The sales resulted in a decrease in the directly held shares but the entities maintain indirect beneficial ownership through various investment partnerships.
• The report indicates that OrbiMed Advisors exercises voting and investment power through a management committee.
• The reporting persons disclaim beneficial ownership of the securities except to the extent of their pecuniary interest.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it primarily reports transactions. The fact that a major shareholder is selling shares could be seen as slightly negative, but without more context, it's difficult to assess the overall impact.

Negatives

• OrbiMed Advisors reduced its direct holdings in Disc Medicine, which could be interpreted negatively by the market.

Risks

• Continued sales of shares by major holders like OrbiMed could put downward pressure on the stock price.
• The complex structure of indirect ownership could create uncertainty for investors.

Management Comments

• The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price.
• Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the 'Exchange Act'), except to the extent of its pecuniary interest therein, if any.
• This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders or major shareholders of a publicly traded company buy or sell the company's stock; this filing indicates changes in OrbiMed's position in Disc Medicine.

Stakeholder Impact

• Shareholders may react to the news of OrbiMed's stock sales.
• The transactions could affect the stock price of Disc Medicine.

Key Dates